Research programme: inflammatory bowel disease therapies - VesiCURE Therapeutics
Latest Information Update: 09 May 2024
At a glance
- Originator VesiCURE Therapeutics
- Class Anti-inflammatories; Exosome therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases